Head to head
Amylyx Pharmaceuticals vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: AMLX · TAK
AMLX
Amylyx Pharmaceuticals
26.02-0.69%
1-year price shape — +92% over the period
Quant Rating C · 95/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
| AMLX | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 26.02 | 21.77 |
| Change today | -0.69% | +1.68% |
| 1-year return | +91.7% | +57.5% |
| Market cap | $3.35B | $69.76B |
| 52-week range | 10.83 – 41.14 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | -18.20 | 311.00 |
| P/E percentile, own 5-yr range | 3rd | 100th |
| P/B | 4.44 | 1.50 |
| Dividend yield | 0.00% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | -1.53 | -0.30 |
| Net profit (TTM) | $-196.70M | $-970.94M |
| Revenue (TTM) | $0 | $4.69T |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | -- | +6.7% |
| Gross margin | -42.6% | 65.8% |
| Operating margin | -292.6% | 14.3% |
| Net margin | -345.4% | 0.9% |
| Free cash flow (TTM) | $-130.02M | $433.95B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 97.8% | 51.3% |
| Insider activity (12mo) | 22 buy / 28 sell | 19 buy / 31 sell |
| Short interest (% of float) | 10.2% | 0.1% |
| Analyst consensus | 100% buy (9) | 100% buy (1) |
| Analyst price target | $46 (+78%) | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | C (95) | C (90) |
| Company | ||
| Employees | 136 | 47,029 |
| Founded | 2013 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.